Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 5 records in total 5
    records per page

    Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation For Anti-Hypertensive Drug in Renal Cell Carcinoma MESHD Renal Cell Carcinoma HP

    Authors: Kihun Kim; Yeji Ko; Dai Sik Ko; Yun Hak Kim

    doi:10.21203/ Date: 2020-07-27 Source: ResearchSquare

    Background: Owing to its worldwide spread, the coronavirus disease MESHD (COVID-19) epidemic was declared a pandemic by the World Health Organization on March 11, 2020. Angiotensin-converting enzyme 2 (ACE2) is the outer surface protein of the cell membrane that is abundantly distributed in the heart, lungs, and kidneys, and plays an important role in molecular docking of the severe acute respiratory syndrome MESHD coronavirus 2. In this study, we aimed to analyze the difference in the survival rate according to ACE2 expressions in pan-cancer. Methods: The clinical and genomic data of pan-cancer patients were accessed from The cancer Genome Atlas. To identify the prognostic significance of ACE2, we used Kaplan-Meier with log-rank test, and the Cox proportional hazards regression to analyze prognostic significance. Results: In the Kaplan-Meier curve, clear cell renal cell carcinoma HP renal cell carcinoma MESHD (ccRCC), uveal melanoma HP melanoma MESHD, and prostate adenocarcinoma MESHD showed statistically significant. In the Cox regression, thyroid carcinoma HP carcinoma MESHD and glioblastoma MESHD glioblastoma multiforme HP multiforme, and ccRCC showed significant results. Only ccRCC had statistically significant, and high ACE2 expression is related to good prognosis. Conclusions: It is known that ACE inhibitor, a primary antihypertensive agent, increases ACE2 expression. Based on these results, we believe that the ACE inhibitor will be important to increase the lifespan of ccRCC patients. This study is the first research to offer a recommendation on the use of anti-hypertensive drugs to ccRCC patients.

    The potential effect of the angiotensin-converting enzyme 2 (ACE2) receptor of 2019-nCoV on lung adenocarcinoma MESHD lung adenocarcinoma HP patients

    Authors: qin huo; zhenwei li; ling shao; siqi chen; jiaying li; ni xie

    doi:10.21203/ Date: 2020-07-25 Source: ResearchSquare

    BackgroundThe 2019-nCoV epidemic is the public health emergency MESHD that has had the greatest impact on the world. Our study aimed to better understand the underlying mechanisms and function of angiotensin-converting enzyme 2 (ACE2) receptor of 2019-nCoV on lung adenocarcinoma MESHD lung adenocarcinoma HP patients (LUAD), and provide a theoretical basis for early diagnosis, prognosis and targeted therapy of 2019-nCoV. MethodsThis study focuses on the expression level, functions, mutation rate, and copy number variations (CNVs) of ACE2 in LUAD using an extensive bioinformatics data mining process. The interaction between ACE2 expression and clinical-pathological parameters of patients with LUAD was investigated using UALCAN. Also, the essential biological features, single nucleotide variations (SNVs), CNVs, and pathway activities of genes interacting with ACE2 in these cancers were further analyzed. ResultsWe found that ACE2 expression in LUAD patients increased with age TRANS, but it was not related to cancer status, patient’s race, patient’s gender TRANS, or patient’s smoking habits. Moreover, our results showed that compared to that in normal tissues, ACE2 was highly expressed in colon adenocarcinoma HP adenocarcinoma MESHD (COAD), kidney renal papillary cell carcinoma HP carcinoma MESHD (KIRP), pancreatic adenocarcinoma HP adenocarcinoma MESHD (PAAD), rectum adenocarcinoma MESHD (READ), and stomach adenocarcinoma MESHD (STAD). However, there is no significant difference in the expression of ACE2 in patients of different ages TRANS. ConclusionsThese findings demonstrate the importance of ACE2 in LUAD, and provide insights into the regulatory mechanisms and function of ACE2.

    Incidental 18F-FDG PET/CT finding of COVID-1 pneumonia MESHD pneumonia HP in asymptomatic TRANS patient diagnosed with lung abscess MESHD lung abscess HP metastasis

    Authors: Antoni Mestre-Fusco; Mònica Velasco-Nuño; Montserrat Negre-Busó; Núria Ferran; Sergi Juanpere; Antoni Rubió

    doi:10.21203/ Date: 2020-05-20 Source: ResearchSquare

    A 66-year-old male TRANS patient, with chronic respiratory disease MESHD and right colon resection in March 2017 for colon low-grade adenocarcinoma MESHD was assessed for recurrence MESHD suggested by elevated levels of tumor marker and no evidence of oncological disease MESHD by CT scan. 18F-FDG PET/CT showed bilateral multiple peripheral FDG-avid foci that matched with a peripheral predominant ground-glass opacities (GGOs) observed in lower lobes and multiple FDG-positive enlarged lymph nodes were also identified in the mediastinum. Patient was hospitalized in March 14th 2020, one day after PET/CT scan, with cough MESHD cough HP, wheezing HP and fever MESHD fever HP, and was treated with anti-inflammatory drugs. A first SARS-CoV-2 RT-PCR in March 15th resulted as negative and patient was treated with antibiotic therapy lead to an improvement of respiratory symptoms. PET/CT scan was interpreted as a pneumonia MESHD pneumonia HP foci. A deteriorating patient condition was observed, with respiratory symptomatology progression, fatigue MESHD fatigue HP and D-Dimer elevation and a new RT-PCR resulted positive. A week after PET/CT scan, hospitalization in intensive care unit was necessary for rapidly disease progression MESHD and severe respiratory distress HP syndrome MESHD and patient died four days later.

    Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection

    Authors: Bernhard Ellinger; Denisa Bojkova; Andrea Zaliani; Jindrich Cinatl; Carsten Claussen; Sandra Westhaus; Jeanette Reinshagen; Maria Kuzikov; Markus Wolf; Gerd Geisslinger; Philip Gribbon; Sandra Ciesek

    doi:10.21203/ Date: 2020-04-20 Source: ResearchSquare

    To identify possible candidates for progression towards clinical studies against SARS-CoV-2, we screened a well-defined collection of 5632 compounds including 3488 compounds which have undergone clinical investigations (marketed drugs, phases 1 -3, and withdrawn) across 600 indications. Compounds were screened for their inhibition of viral induced cytotoxicity using the human epithelial colorectal adenocarcinoma MESHD cell line Caco-2 and a SARS-CoV-2 isolate. The primary screen of 5632 compounds gave 271 hits. A total of 64 compounds with IC50 <20 µM were identified, including 19 compounds with IC50 < 1 µM. Of this confirmed hit population, 90% have not yet been previously reported as active against SARS-CoV-2 in-vitro cell assays. Some 37 of the actives are launched drugs, 19 are in phases 1-3 and 10 pre-clinical. Several inhibitors were associated with modulation of host pathways including kinase signaling P53 activation, ubiquitin pathways and PDE activity modulation, with long chain acyl transferases were effective viral inhibitors.

    Pulmonary Pathology of Early Phase 2019 Novel Coronavirus (COVID-19) Pneumonia MESHD Pneumonia HP in Two Patients with Lung Cancer

    Authors: Sufang Tian; Weidong Hu; Li Niu; Huan Liu; Haibo Xu; Shu-Yuan Xiao

    id:10.20944/preprints202002.0220.v2 Date: 2020-03-02 Source:

    There is currently a lack of pathologic data on the novel coronavirus (SARS-CoV-2) pneumonia MESHD pneumonia HP, or COVID-19, from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma MESHD were retrospectively found to have had COVID-19 at the time of surgery. These two cases thus provide important first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that, apart from the tumors, the lungs of both patients exhibited edema MESHD edema HP, proteinaceous exudate, focal reactive hyperplasia MESHD of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Since both patients did not exhibit symptoms of pneumonia MESHD pneumonia HP at the time of surgery, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia MESHD pneumonia HP.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.